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los pacientes con resultado positivo de un estudio electrofisiológico. En el análi-
sis para los pacientes no isquémicos la costo efectividad depende del escenario 
escogido, superando algunas veces el umbral y otras no. En general, los resultados 
son sensibles a cambios en variables como el horizonte temporal, las probabilidades 
de muerte y el precio del CDI.
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Objectives: To assess, describe and compare the requirements and pathways 
of medical devices from licensing to coverage in four Latin American countries 
(LAC) health systems. MethOds: We conducted a literature search (February 2015) 
on Pubmed, Lilacs and Value in Health Regional Issues journal. We also searched 
specific websites of Health Technology Assessment (HTA) and regulatory agencies, 
ministries of health and health agencies; and a performed generic Internet search. 
We included all publications describing aspects related to regulation, coverage, 
medical technology innovation, and HTA and Economic Evaluation (EE) guidelines. 
We additionally interviewed key informants from all countries to gather informa-
tion related to the aforementioned processes. We present here the literature search 
results. Results: We included 60 studies out of 2190. Five percent of the publica-
tions analyzed the four countries jointly, 75% were from Brazil, 8.3% from Mexico, 5% 
from Colombia and 5.7% from LAC in general. Half of the studies described the role 
of the HTA and EE in decision-making and aspects or policies related to innovation 
(25% and 23.3%). Regarding the description of the coverage process, it was addressed 
in 13.3% of the studies; 10% of the publications focused on technovigilance; and also 
10% on regulatory aspects. Remaining publications were methodological guidelines 
and general descriptions of the health systems and the role of medical devices. All 
countries had HTA and EE guidelines, although there did not include device specific 
recommendations. There is a spectrum of HTA formalization for technology incor-
poration after licensing, higher in Brazil and lower in Argentina cOnclusiOns: 
There is scarce information on the processes and requirements to achieve coverage 
for medical devices in these countries. Processes differ, are in general not explicit, 
lack transparency, and usually replicate those of drugs not taking into account the 
specificities of medical devices.
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Objectives: Hemorrhoids are not life-threatening, but they can cause itching, 
bleeding and pain, worsening quality of life. Stapled haemorrhoidopexy (SH) is a 
specially designed circular stapler used to cut out a strip of the tissue above the 
hemorrhoids in an area of the rectum that doesn’t feel much pain. The operation 
helps to reduce the hemorrhoids and it also helps shrink the remaining hemor-
rhoids by reducing their blood supply and makes them less likely to extend out 
of the anus. The aim of this study was to review and analyze the evidence of 
SH. MethOds: The electronic databases PubMed, EMBASE, The Cochrane Central 
Register of Controlled Trials, Wiley and OVID, were reviewed. The date limit was set 
to February 10th of 2015. The studies included were, RCT, the intervention being SH, 
and the comparison, conventional surgical techniques (CST). The primary outcome 
was to evaluate the patient acceptability and the second outcome was to evaluate 
length of stay, pain and time to return to work, only English language was recov-
ered. Quality was assessed with GRADE scale. Meta-analysis was conducted with 
RevMan 5.3 for patient acceptability and length of stay, by random effect. Results: 
65 records were identified in all databases described, 6 records met the inclusion 
criteria (n= 1503) comparing the SH with CST with a mean follow-up of 15 months. 
Patient preference was higher in SH compared with CST (OR 1.51[1.03-2.2]; I2:26%, 
p= 0.03.) Length of Stay was significantly lower in SH group (MD -0.74[-1.27;-0.21]; 
I2:96%, p< 0.00001, n= 1299). Adverse events were similar between strategies. SH 
offers less post-operative pain and fast return to work activities. cOnclusiOns: 
SH is a safe and effective treatment to treat hemorrhoids grade III and IV, improve 
hospital efficiency and has higher patient acceptability.
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Objectives: Cost-Effectiveness analysis of Drug Coated Balloon (DCB) vs. 
Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of 
Peripheral Arterial Disease in lower limbs from Public Healthcare System (SUS) in 
Brazil. MethOds: An analytical decision model was considered with Target Lesion 
Restenosis (TLR) Avoided and total cost at the end of two year period as endpoints. 
An Excel model was developed. Effectiveness data was taken from a pooled analysis 
and second revascularization procedures probabilities were taken with KOL crite-
rion. A public Healthcare System (SUS) payer perspective was assumed. Total direct 
costs for reimbursement were taken from Tabnet/Datasus–2014. Because effective-
ness and cost were taken as unique values at the end of the two years, discount 
rate was no applied. Sensitivity Univariate analysis was done for DEB vs. PTA. For 
the Probabilistic Sensitivity Analysis a Monte Carlo Simulation with 1000 iterations 
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Objectives: To estimate the demand, implementation costs, and economic 
impact of Butantan’s one-dose tetravalent dengue vaccine in Brazil. MethOds: 
We modeled the supply and demand of dengue vaccine nationally and for 6 key 
states using an existing strategic demand forecasting model. Input parameters 
on disease burden, vaccine product and pricing, production capacity, introduction 
strategies, and implementation costs were derived from local Brazilian stakehold-
ers. Country-specific epidemiological data were obtained from disease reporting 
systems. Algorithms were developed to model 30 year dengue vaccine demand, total 
implementation cost, and vaccine impact using different age group introduction 
scenarios. Brazil’s highest dengue burden is among adults 19-46, and strategies tar-
geting adults were modeled with the traditional child population. Results: Initial 
strategies targeting all ages or ≥ 15 year olds exceeded capacity and were considered 
not feasible. The demand for all strategies was below capacity for all scenarios, but 
by year 2048, the demand including boosters exceeds capacity for adult scenarios 
except for ages 19-31 (86.73M) and 31-46 (117.06M). At $5 per dose, the average 
annual total cost of introduction ranged from $21.05-$322.21M in the first 10 years 
and $52.58-844.13M in the last 10 years. The most affordable scenario is children 
1-2 years, but this scenario had little impact on the disease burden (34% reduction 
in last 10 years). The combination scenario (staggered vaccine introduction for 2-46 
year olds for 5 years followed by 1-2 year olds) has the greatest impact with 90% 
and 79% reduction in cases and deaths respectively, and 84% annual treatment cost 
savings. cOnclusiOns: Vaccinating adults followed by children yields the greatest 
vaccine impact. Vaccine price, introduction strategies, age, and production capacity 
are major drivers of the demand and require consideration when deciding vaccine 
introduction. Dengue vaccine has the potential to reduce cases and associated costs 
substantially based on various introduction scenarios.
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Objectives: A systematic review was used to assess economic costs of bacterial 
meningitis. MethOds: PubMed, Scopus and NHS-EED were searched to identify 
eligible papers. Economic evaluations that cost bacterial meningitis cases were 
selected. Reported direct and indirect costs were converted to 2012 international 
dollars and reported in ranges (minimum and maximum). Results: We identi-
fied 621 non-duplicated articles. 118 papers were selected for full-text revision. 25 
studies accomplished the inclusion criteria and were carried out in 27 countries. 
Most studies were undertaken in high-income countries (n= 17). Only two studies 
took place in low income countries. Minimum and maximum laboratory mean 
costs were found in Burkina Faso (I$ 6) and Chile (I$ 1,604), respectively. Regarding 
to medication costs, the mean minimal cost was I$ 90 (Kenia) and the maximal I$ 
1,284 (Rusia). Chile recorded the higher hospital cost of stay (I$ 9,144) and Burkina 
Faso the lower (I$ 107). Out-of-pocket health expenditures were estimated only 
in one study (Senegal, I$ 2,444). Among high income countries studies, the higher 
and lower total costs were reported in the United States and Suiza (I$151,449 – 
I$3,804). cOnclusiOns: A large cost variability was found in the included studies. 
High-income countries economic costs were superior versus low-income countries 
costs. Even though Subsaharian countries has a high bacterial meningitis incidence, 
only three studies were undertaken in this area.
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Objectives: determinar, desde la perspectiva del sistema de salud colombiano, la 
relación de costo efectividad del uso de un CDI en comparación con no hacerlo, para 
evitar la muerte súbita en pacientes con cardiomiopatía isquémica o no isquémica, 
FE menor al 35%, DSVI y estadio NYHA II-III. MethOds: se desarrolló un modelo 
de Markov que incluia costos, efectividad, calidad de vida y supervivencia para 
un horizonte de base de 10 años. Las probabilidades de transición se extrajeron 
de estudios identificados en la literatura. La valoración de los recursos se realizó 
mediante consultas a fabricantes del dispositivo, a manuales tarifarios y al sistema 
nacional de información de medicamentos. Se realizaron análisis de sensibilidad 
probabilísticos y determinísticos. Results: en el caso base, considerando conjun-
tamente pacientes isquémicos y no isquémicos, el CDI en comparación con la TFO 
reporta una RICE de $30.345.73 por AVAC. En el análisis de subgrupos, para los 
pacientes isquémicos la RICE es de $33.412.184 por AVAC, en los no isquémicos 
es de $47.030.266 por AVAC, y para pacientes con resultado positivo de un estudio 
electrofisiológico es de $19.558.355 por AVAC. Considerando una disposición a pagar 
de tres veces el PIB per cápita del 2013 ($45.026.378), la probabilidad de que el CDI 
sea costo efectivo es del 97,5%. cOnclusiOns: El uso de un CDI para prevenir la 
muerte súbita en pacientes con FC es una estrategia costo efectiva para el sistema 
de salud colombiano, en especial para el subgrupo de pacientes isquémicos y para 
